Suchergebnisse - "Kosakai, Yoshinori"

PubPharm (12)

1

Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan : A real-world administrative database analysis

enthalten in: Journal of diabetes investigation | 2024

von Kashiwagi, A. | Shoji, S. | Kosakai, Y. | +2

2

Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan : A real-world data analysis

enthalten in: Diabetes, obesity & metabolism | 2024

von Takahashi, H. | Asakawa, K. | Kosakai, Y. | +2

3

Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus : A Single-Arm Multicenter Interventional Study

enthalten in: Clinical drug investigation | 2023

von Watanabe, K. | Yamaguchi, S. | Kosakai, Y. | +2

4

Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study

enthalten in: Clinical drug investigation | 2023

von Watanabe, K. | Yamaguchi, S. | Kosakai, Y. | +2

5

Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor : A real-world administrative database study in Japan

enthalten in: Journal of diabetes investigation | 2023

von Kashiwagi, A. | Shoji, S. | Kosakai, Y. | +3

6

Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan : A real-world administrative database analysis

enthalten in: Diabetes research and clinical practice | 2022

von Abiru, N. | Shoji, S. | Kosakai, Y. | +3

7

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor : A real-world retrospective administrative database analysis in Japan

enthalten in: Journal of diabetes investigation | 2022

von Kashiwagi, A. | Shoji, S. | Onozawa, S. | +3

8

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor : A real‐world retrospective administrative database analysis in Japan

enthalten in: Journal of Diabetes Investigation | 2022

von Kashiwagi, A. | Shoji, S. | Onozawa, S. | +3

9

Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

enthalten in: Clinical drug investigation | 2019

von Ishihara, H. | Yamaguchi, S. | Sugitani, T. | +1

10

Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

enthalten in: Clinical drug investigation | 2019

von Ishihara, H. | Yamaguchi, S. | Sugitani, T. | +1